Journal of Industrial Convergence (산업융합연구)

DAEHAN Society of Industrial Management (대한산업경영학회)
권호 표지
DOI QR코드

DOI QR Code

Experience of Patients with Mucopolysaccharide Receiving Enzyme Replacement Therapy

효소보충치료(ERT)를 받고 있는 뮤코다당증 환자의 경험

  • Received : 2021.05.21
  • Accepted : 2021.08.20
  • Published : 2021.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study was to explore the meaning of the experience of Mucopolysaccharidosis patients receiving Enzyme Replacement Therapy(ERT). A qualitative research design was adopted. The participants were 7 patients diagnosed with MPS who is receiving ERT for several years. Data were collected through in-depth interviews from 1 July 2018 to 22 July 2018 for seven adult patients with MPS receiving ERT. Individual interviews were recorded, and transcribed data were analyzed using the inductive method of content analysis. The final 4 categories and 15 subcategories were identified. The 4 categories of the experience of Mucopolysaccharidosis patients receiving ERT were "Physical and psychological changes through ERT", "Continuous tunnel called ERT", "Accepting the reality" and "Cautious hope". This study provides deep insight into the experience of Mucopolysaccharidosis patients receiving ERT. Medical staff including nurses and related organizations should concern their distress during ERT as well as physical symptoms.

본 연구는 효소보충치료(ERT)를 받고 있는 뮤코다당증 환자들의 경험을 파악하기 위한 목적으로 수행되었다. 본 연구는 질적 연구방법을 적용하였고, 효소보충치료를 받고 있는 7명의 뮤코다당증 성인환자를 대상으로. 2018년 7월 1일부터 2018년 7월 22일까지 심층 인터뷰를 통해 자료를 수집하였다. 수집된 개별 면담 자료는 필사하여 귀납적 내용 분석 방법으로 분석하였다. 연구결과, 효소보충치료를 받고 있는 뮤코다당증 환자의 경험은 최종 4개의 범주(효소보충치료를 통한 신체·심리적 변화, 효소보충치료라는 계속되는 터널, 치료에 대한 현실 받아들이기, 조심스러운 희망)와 15개의 하위범주로 도출되었다. 따라서, 의사 및 간호사는 효소보충치료를 받고 있는 뮤코다당증 환자의 이러한 경험을 고려하여 돌봄을 제공해야 할 것이고, 정부 또한 뮤코다당증 환자의 신체적 증상 뿐 아니라 효소보충치료로 인한 어려움을 고려한 실질적인 정책을 마련할 필요가 있다. 본 연구는 희귀질환인 뮤코다당증 환자의 경험을 확인하였다는 점에서 의의가 있다.

Keywords

References

  1. Article 2 of the Rare Disease Control Act(2020.09.12.), https://www.law.go.kr/LSW/eng/engLsSc.do?menuId=2§ion=lawNm&query=RARE+DISEASE+MANAGEMENT+ACT&x=27&y=25#liBgcolor1)
  2. Muenzer, J. (2004). The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. Journal of Pediatrics, 144(5Suppl), S27-34. DOI: 10.1016/j.jpeds.2004.01.052
  3. Khan S. A. et al. (2017). Epidemiology of mucopolysaccharidoses. Molecular Genetics and Metabolism, 121(3), 227-240. DOI: 10.1016/j.ymgme.2017.05.016
  4. Wang R. Y. et al. (2009). Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II. Molecular Genetics and Metabolism, 98(4), 406-411. DOI: 10.1016/j.ymgme.2009.07.015
  5. Y. B. Sohn. (2014). Long-term therapeutic effects of mucopolysaccharidoses and efforts to overcome limitations. Journal of Genetic and Metabolism in Korea, 14(1), 29-36.
  6. Buraczewska, M., O'Leary, D., Walsh, O., Monavari, A. & Crushell, E. (2013). Parental experience of enzyme replacement therapy for Hunter syndrome. Irish Medical Journal, 106(4), 120-122.
  7. Bitencourt, F. H., Vieira, T. A., Steiner, C. E., Neto, J. C., Boy, R. & Schwartz, IVD. (2015). Medical Costs Related to Enzyme Replacement Therapy for Mucopolysaccharidosis Types I, II, and VI in Brazil: A Multicenter Study. Value Health Reg 8, 99-106. DOI: 10.1016/j.vhri.2015.08.002
  8. Ministry of Health and Welfare. (2018). Increase the scope of rare diseases and increase support such as medical expenses "First announcement of a total of 927 designated list of rare diseases subject to state management". [Internet].2018 September[ cited 2018 September 17].Available from:http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=1&CONT_SEQ=346076
  9. Y. B. Sohn., S. Y. Cho, J. E. Lee, Y. H. Kwun, R. Huh & D. K. Jin. (2015). Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome. Molecular Genetics and Metabolism, 114(2), 156-160. DOI: 10.1016/j.ymgme.2014.08.009
  10. Franco, J. et al. (2017). Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: Results from a single-center case series study. Intractable Rare Dis Res, 6(3), 183-190. DOI: 10.5582/irdr.2017.01036
  11. Gomes, D. F., Gallo, L. G., Leite, B. F., Silva, R. B. & da Silva, E. N. (2019). Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: Systematic review. Journal of Inherited Metabolic Disease, 42(1), 66-76. DOI: 10.1002/jimd.12028
  12. S. Y. Kang. (2012). Life experiences of mothers in parenting children with Hunter's syndrome. Journal of Korean Academy of Nursing, 42(5), 609-621. DOI: 10.4040/jkan.2012.42.5.609
  13. H. S. Park & K. B. Kim. (2013). The Experience of Parents of Children with Mucopolysaccharidosis. The Academy of Qualitative Research, 14(1), 1-12. https://doi.org/10.22284/qr.2013.14.1.1
  14. Somanadhan, S. & Larkin, P. J. (2016). Parents' experiences of living with, and caring for children, adolescents and young adults with Mucopolysaccharidosis (MPS). Orphanet Journal of Rare Diseases, 11(1), 138. https://doi.org/10.1186/s13023-016-0521-0
  15. Guba, E. G. & Lincoln, Y. S. (1994). Competing paradigms in qualitative research. Handbook of qualitative research. Thousand Oaks: Sage Publications, 105-117.
  16. Elo, S. & Kyngas, H. (2008). The qualitative content analysis process. Journal of Advanced Nursing, 62(1), 107-115. DOI: 10.1111/j.1365-2648.2007.04569.x
  17. Chinn, Peggy L. (Peggy Lois), Kramer & Maeona K. (1999). Theory and nursing : integrated knowledge development (5th ed). St. Louis: Mosby.
  18. S. H. Choi, J. H. Jung & S. W. Jung. (2016). Concept and procedures of qualitative content analysis. Journal of Qualitative Inquiry, 2(1), 127-155.
  19. Robson, C. (1993). Real world research: A resource for social scientists and practitioner-researchers. Oxford: Blackwell.
  20. Muenzer, J., Gucsavas-Calikoglu, M., McCandless, S. E., Schuetz, T. J. & Kimura, A. (2007). A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Molecular genetics and metabolism, 90(3), 329-337. DOI: 10.1016/j.ymgme.2006.09.001
  21. Laraway, S., Mercer, J., Jameson, E., Ashworth, J., Hensman, P. & Jones, S. A. (2016). Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I. Journal of Pediatrics, 178, 219-226.e211. DOI: 10.1016/j.jpeds.2016.08.033
  22. A. R. Yang, J. S. Kim, S. Y. Cho & D. K. Jin. (2017). A Review of Recent Research in Treatment Approaches of Mucopolysaccharidosis (MPS). Journal of mucopolysaccharidosis and rare disease, 3(2), 37-40. https://doi.org/10.19125/JMRD.2017.3.2.37
  23. D. K. Jin. (2011). Enzyme replacement therapy. Journal of The Korean Society of Inherited Metabolic disease, 11(1), 27-32.
  24. Harmatz, P., Hendriksz, C. J., Lampe, C., McGill, J. J. & Parini, R. (2017). Leao-Teles E, et al. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Molecular Genetics and Metabolism, 122(1-2), 107-112. DOI: 10.1016/j.ymgme.2017.03.008
  25. G. S. Lee. (2018). A Study on the Anxiety Experience of Disabled Person with Progressive Rare Disease. Korean Journal of Social Welfare, 70(2), 247-273. https://doi.org/10.20970/kasw.2018.70.2.010
  26. Ministry of Health and Welfare. (2017). Preparation of a roadmap for systematic diagnosis, treatment and management of rare diseases. [Internet].[2017 December 29].Available from:http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=343355
  27. K. S. Lee & Y. C. Min. (2008). Psychological Adjusting Process to Diseases in People with Chronic Illnesses. Journal of the Psychiatric Nursing Society, 17(2), 151-160.
  28. The Economist Intelligence Unit Limited. (2020). Suffering in silence: Assessing rare disease awareness and management in Asia-Pacific, https://eiuperspectives.economist.com/sufferingsilence-rare-disease-asia-pacific